Epidemiology of Cardiotoxicity in Children With Cancer
2 other identifiers
observational
N/A
0 countries
N/A
Brief Summary
To provide a comprehensive analysis of risk factors for the development of clinical cardiotoxicities in over 6,000 children with cancer who had been treated on standardized protocols involving the use of anthracyclines alone or in combination with other potentially cardiotoxic therapies or with no use of anthracycline therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
Started Apr 1992
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
April 1, 1992
CompletedStudy Completion
Last participant's last visit for all outcomes
March 1, 1994
CompletedFirst Submitted
Initial submission to the registry
May 25, 2000
CompletedFirst Posted
Study publicly available on registry
May 26, 2000
CompletedMarch 16, 2016
September 1, 2001
May 25, 2000
March 15, 2016
Conditions
Eligibility Criteria
Contact the study team to discuss eligibility requirements. They can help determine if this study is right for you.
Sponsors & Collaborators
Related Publications (1)
Krischer JP, Epstein S, Cuthbertson DD, Goorin AM, Epstein ML, Lipshultz SE. Clinical cardiotoxicity following anthracycline treatment for childhood cancer: the Pediatric Oncology Group experience. J Clin Oncol. 1997 Apr;15(4):1544-52. doi: 10.1200/JCO.1997.15.4.1544.
PMID: 9193351BACKGROUND
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Sponsor Type
- NIH
Study Record Dates
First Submitted
May 25, 2000
First Posted
May 26, 2000
Study Start
April 1, 1992
Study Completion
March 1, 1994
Last Updated
March 16, 2016
Record last verified: 2001-09